Mitsuo Obana
Kanagawa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: June 17, 2021
Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.
Journal: Diabetes technology & therapeutics
Published: February 05, 2020
Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus.
Journal: Journal of clinical medicine research
Published: August 14, 2019
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Journal: Journal of diabetes research
Published: January 09, 2019
Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
Journal: Journal of clinical medicine research
Published: November 02, 2018
Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
Journal: Clinical and experimental hypertension (New York, N.Y. : 1993)
Published: October 31, 2018
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Journal: Diabetes & vascular disease research
Published: October 05, 2018
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: May 25, 2017
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Journal: Journal of clinical medicine research
Published: April 11, 2017
Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: February 15, 2016
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: January 20, 2016
Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.
Journal: Journal of clinical medicine research
Published: December 04, 2015
Last Updated: 09/26/2026